Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
anti-KRAS G12D mTCR PBL in HLA-A*11:01 Patients with RAS G12D-expressing Cancers
NCT03745326Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2019
- Primary completion
- Aug 2022
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of anti-KRAS G12D mTCR PBL in gastrointestinal cancer, pancreatic cancer (PC), gastric cancer (GC) and 2 more (2 arms), sponsored by National Cancer Institute. Primary endpoints: Adverse Events up to 2.3 months, Dose-Limiting Toxicities up to 1 month and 1 more. Started May 2019; status: terminated.
02
Drugs
anti-KRAS G12D mTCR PBL
03
Conditions
gastrointestinal cancerpancreatic cancer (PC)gastric cancer (GC)colon cancerrectal cancer
Beyond the preview
Go deeper on NCT03745326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745326.